Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GENNEX LAB. vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GENNEX LAB.   ACTAVIS
EQUITY SHARE DATA
    GENNEX LAB.
Mar-23
ACTAVIS
Dec-18
GENNEX LAB./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs916,159-   
Low Rs510,840-   
Sales per share (Unadj.) Rs3.43,963.8-  
Earnings per share (Unadj.) Rs0.3-1,276.8-  
Cash flow per share (Unadj.) Rs0.3417.7-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs4.516,349.0-  
Shares outstanding (eoy) m176.64332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.13.4 60.8%   
Avg P/E ratio x25.0-10.6 -236.1%  
P/CF ratio (eoy) x21.032.3 65.1%  
Price / Book Value ratio x1.50.8 185.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,2294,489,898 0.0%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m790-   
Avg. sales/employee Rs Th078,010.2-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,127.1-  
INCOME DATA
Net Sales Rs m5931,318,372 0.0%  
Other income Rs m4025,212 0.2%   
Total revenues Rs m6331,343,584 0.0%   
Gross profit Rs m4734,548 0.1%  
Depreciation Rs m9563,576 0.0%   
Interest Rs m1476,078 0.0%   
Profit before tax Rs m64-579,893 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,896 0.0%   
Tax Rs m15-7,349 -0.2%   
Profit after tax Rs m49-424,648 -0.0%  
Gross profit margin %7.92.6 301.7%  
Effective tax rate %22.81.3 1,798.1%   
Net profit margin %8.3-32.2 -25.7%  
BALANCE SHEET DATA
Current assets Rs m487540,727 0.1%   
Current liabilities Rs m295478,345 0.1%   
Net working cap to sales %32.34.7 682.6%  
Current ratio x1.61.1 145.9%  
Inventory Days Days420 20.6%  
Debtors Days Days57,912,58966 87,337,463.5%  
Net fixed assets Rs m835149,232 0.6%   
Share capital Rs m1800-   
"Free" reserves Rs m6230-   
Net worth Rs m8045,437,670 0.0%   
Long term debt Rs m1631,914,801 0.0%   
Total assets Rs m1,3228,500,316 0.0%  
Interest coverage x5.7-6.6 -86.2%   
Debt to equity ratio x0.20.4 57.6%  
Sales to assets ratio x0.40.2 289.5%   
Return on assets %4.7-4.1 -115.8%  
Return on equity %6.1-7.8 -78.4%  
Return on capital %8.0-4.8 -165.2%  
Exports to sales %42.10-   
Imports to sales %13.60-   
Net fx Rs m1640-   
CASH FLOW
From Operations Rs m237471,005 0.1%  
From Investments Rs m-383258,756 -0.1%  
From Financial Activity Rs m210-808,385 -0.0%  
Net Cashflow Rs m64-78,232 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare GENNEX LAB. With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GENNEX LAB. With: ISHITA DRUGS  CAPLIN POINT  AMRUTANJAN HEALTHCARE  GANGA PHARMACEUTICALS  LYKA LABS  



Today's Market

Sensex Today Tanks 500 Points Amid Iran-Israel Tensions | Nifty Below 21,850 | All Sectors in Red Sensex Today Tanks 500 Points Amid Iran-Israel Tensions | Nifty Below 21,850 | All Sectors in Red(10:30 am)

Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.